Date: 2016-10-25
Type of information: Collaboration agreement
Compound: biomarker analysis
Company: Myriad RBM, a wholly-owned subsidiary of Myriad Genetics (USA - UT) Sanofi (France)
Therapeutic area: Cardiovascular diseases - Metabolic diseases
Type agreement: collaboration
Action mechanism: biomarker.
Disease: prediction of cardiovascular and microvascular (renal and retinal) risk in people with type 2 diabetes
Details: * On October 25, 2016, Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, announced that it will work with Sanofi to perform a biomarker analysis of blood samples from the evaluation of lixisenatide in acute coronary syndrome (ELIXA) trial (NCT01147250). Under the agreement, Sanofi will provide approximately 5,300 serum samples from the ELIXA trial. Myriad RBM will use its CustomMAP® platform to measure biomarkers that can predict cardiovascular and microvascular (renal and retinal) risk in people with type 2 diabetes. Myriad RBM's DiscoveryMAP® platform was used with Sanofi's ORIGIN1 trial to successfully identify biomarkers associated with cardiovascular events or death in people with pre-diabetes or early type 2 diabetes. The performance of these biomarkers was confirmed using Myriad RBM's CustomMAP platform and samples from Sanofi's HOPE trial. "In prior studies, we demonstrated the power of DiscoveryMAP to identify panels of biomarkers that have important diagnostic and prognostic applications for people at a higher risk of a cardiovascular event. This new agreement with Sanofi will expand upon that experience," said Ralph McDade, Ph.D., president of Myriad RBM. "Our ultimate goal is to provide accurate estimates of the risk of a future cardiovascular event in patients so that drug developers and physicians can tailor care and achieve better health outcomes."
Financial terms: Financial terms of the deal were not disclosed.
Latest news:
